Briumvi (ublituximab): EU-authorised infusion treatment for active relapsing MS
Published by MyelinWatch:
Briumvi (ublituximab) · Ublituximab is a laboratory-made antibody that attaches to CD20, a marker on B cells, a type of white blood cell involved in MS inflammation, and removes many of these cells. Briumvi is given as an infusion into a vein: 150 mg first, 450 mg two weeks later, then 450 mg every 24 weeks. Before each infusion, people receive a corticosteroid and an antihistamine to reduce infusion reactions. The two Phase 3 ULTIMATE studies compared it with teriflunomide, an MS medicine taken by mouth.
What is being studied
Ublituximab is a laboratory-made antibody that attaches to CD20, a marker on B cells, a type of white blood cell involved in MS inflammation, and removes many of these cells. Briumvi is given as an infusion into a vein: 150 mg first, 450 mg two weeks later, then 450 mg every 24 weeks. Before each infusion, people receive a corticosteroid and an antihistamine to reduce infusion reactions. The two Phase 3 ULTIMATE studies compared it with teriflunomide, an MS medicine taken by mouth.
Research stage
Phase 3 study in people
EU-authorised for adults with relapsing MS with active disease; ULTIMATE I and II completed
What we know so far
The EU authorised Briumvi on 31 May 2023 for adults with relapsing forms of MS with active disease, shown by relapses or MRI findings; in the United States it was approved on 28 December 2022. The two identical 96-week ULTIMATE studies enrolled 1,094 people. The yearly relapse rate was 0.08 with ublituximab versus 0.19 with teriflunomide in ULTIMATE I and 0.09 versus 0.18 in ULTIMATE II, and there were fewer active inflammatory lesions on MRI. Disability worsening confirmed after 12 weeks did not differ significantly (5.2% versus 5.9% in the pooled analysis). Infusion-related reactions occurred in 47.7% of people on ublituximab, and serious infections in 5.0% versus 2.9% with teriflunomide; the EU product information says infusion reactions were most frequent with the first infusion. The EU product information requires hepatitis B screening before treatment and warns about infections, including hepatitis B reactivation and PML, a rare brain infection seen very rarely with anti-CD20 antibodies. The US prescribing information, revised in January 2026, also warns of liver injury and requires liver tests before the first dose.
What this means for patients today
Briumvi is an authorised medicine, not an experimental one, but only for adults with relapsing MS with active disease. It is not authorised for children, the studies did not show a significant effect on disability worsening, and it is not evidence of myelin repair. The cited sources do not establish whether Briumvi is available or reimbursed in Greece. The ULTIMATE studies compared it only with teriflunomide, so they do not show how it compares with other anti-CD20 medicines. Further TG Therapeutics studies of a modified dosing schedule, injections under the skin and use in children are accepting participants; none lists a site in Greece. Treatment decisions belong with a neurologist experienced in MS.
- Treatment or approach
- Briumvi (ublituximab) • intravenous anti-CD20 antibody authorised in the EU for adults with relapsing MS with active disease
- How it is intended to work
- Anti-CD20 B-cell depletion by intravenous ublituximab
- Where the study is running
- EU-wide authorisation; Greek availability or reimbursement is not established by the cited sources
- Published by MyelinWatch
- Last substantive MyelinWatch update